Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Varsha Gandhi, PhD, on Ibrutinib

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Jan
17
Today In Oncology
Trastuzumab/Pertuzumab vs Cetuximab/Irinotecan in RAS/BRAF Wild-Type HER2-Positive Metastatic Colorectal Cancer
ACS Annual Report Cancer Mortality Rates Decline but Challenges Remain
Exercise Therapy as Candidate Anticancer Strategy
Extent and Impact of Primary MMRD in Gliomas Among Children, Adolescents, and Young Adults
Adjuvant T-DM1 in Patients With HER2-Positive Breast Cancer: Long-Term Results of the KATHERINE Trial
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo